Latest News about IONS
Recent news which mentions IONS
The 7 Most Hated Stocks by Institutional Traders
September 20, 2023
From InvestorPlace
Hypertension Impacts 1.2B People - Alnylam's Gene Silencing Drug Candidate Hits the Mark in Phase 2 Study, Offering Hope
September 07, 2023
From Benzinga
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
August 07, 2023
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Biogen Reports New Spinraza Data In Atrophy Patients After Incomplete Response To Novartis' Treatment
July 03, 2023
From Benzinga
Hereditary Angioedema Update Solidifies Intellia's Cell Therapy's Competitive Efficacy Profile: Analyst
June 12, 2023
From Benzinga
Analyst Creates Bullish Pitch On Ionis Pharmaceuticals Citing 'Strategic Pivot Underway'
June 07, 2023
From Benzinga
From Benzinga
From Benzinga
From MarketWatch
What's Going On With Biogen Stock Tuesday?
April 25, 2023
From Benzinga
Biogen Announces Additional Cost Cutting Initiatives, Chops Certain Stroke, Gene Therapy Programs
April 25, 2023
From Benzinga
3 Biotech Stocks to Sell Before They’re 6 Feet Under
April 24, 2023
From InvestorPlace
AstraZeneca, Ionis Unveil Complete Phase 3 Data For ATTR Candidate, Says Drug Halts Disease Progression
April 24, 2023
From Benzinga
Could This Rare-Disease Drug Candidate Become a Blockbuster?
April 19, 2023
From Motley Fool
From Benzinga
AstraZeneca-Ionis Partnered Rare Disease Drug Data Shows Sustained Benefit; Drug Under FDA Review
March 27, 2023
From Benzinga
FDA Adcomm Says Benefit-Risk Profile Favor Biogen's Tofersen For Inherited Neuro Disorder
March 23, 2023
From Benzinga
From Benzinga
Wall Street predicts approval for another ALS drug
March 21, 2023
From MarketWatch
Biogen Triumphs In Legal Battle Regarding Tecfidera, Delaying EU Generic Erosion For Another Year
March 16, 2023
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.
Never miss important news. Subscribe to our newsletter.
Register for free
Information
Copyright 2024. BUSINESS INSURANCE HOLDINGS
